Skip to main content
Terug
OCPNF logo

Olympus Corporation

Datakwaliteit: 100%
Oversold
OCPNF
OTC Healthcare Medical - Instruments & Supplies
€ 8,61
€ 0,00 (0,00%)
Marktkapitalisatie: 9,48B
Ook genoteerd als OLYMY OTC
Dagbereik
€ 8,61 € 9,29
52-Weeksbereik
€ 8,00 € 14,00
Volume
15
50D / 200D Gem.
€ 10,83 / € 12,07
Vorige Slotkoers
€ 8,61

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 0,1 0,4
P/B 0,0 2,9
ROE % 15,6 3,7
Net Margin % 11,8 3,8
Rev Growth 5Y % 8,1 10,0
D/E 0,3 0,2

Belangrijkste Punten

Revenue grew 8,09% annually over 5 years — modest growth
Earnings declined -51,41% over the past year
ROE of 15,62% — decent returns on equity
Debt/Equity of 0,30 — conservative balance sheet
Generating 125,25B in free cash flow
P/E of 0,08 — trading at a low valuation

Groei

Revenue Growth (5Y)
8,09%
Revenue (1Y)6,53%
Earnings (1Y)-51,41%
FCF Growth (3Y)112,01%

Kwaliteit

Return on Equity
15,62%
ROIC12,42%
Net Margin11,82%
Op. Margin16,29%

Veiligheid

Debt / Equity
0,30
Current Ratio1,60
Interest Coverage23,75

Waardering

P/E Ratio
0,08
P/B Ratio0,01
EV/EBITDA-0,09
Dividend Yield0,01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 6,53% Revenue Growth (3Y) 6,34%
Earnings Growth (1Y) -51,41% Earnings Growth (3Y) -9,35%
Revenue Growth (5Y) 8,09% Earnings Growth (5Y) 73,80%
Profitability
Revenue (TTM) 997,33B Net Income (TTM) 117,86B
ROE 15,62% ROA 8,23%
Gross Margin 68,55% Operating Margin 16,29%
Net Margin 11,82% Free Cash Flow (TTM) 125,25B
ROIC 12,42% FCF Growth (3Y) 112,01%
Safety
Debt / Equity 0,30 Current Ratio 1,60
Interest Coverage 23,75 Dividend Yield 0,01%
Valuation
P/E Ratio 0,08 P/B Ratio 0,01
P/S Ratio 0,01 PEG Ratio 0,05
EV/EBITDA -0,09 Dividend Yield 0,01%
Market Cap 9,48B Enterprise Value -13,95B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 997,33B 936,21B 881,92B 868,87B 730,54B
Net Income 117,86B 242,57B 143,43B 115,74B 12,92B
EPS (Diluted) 102,80 21,88 108,65 90,17 51,00
Gross Profit 683,70B 625,12B 562,70B 475,99B 427,99B
Operating Income 162,46B 151,89B 186,61B 166,30B 102,50B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,43T 1,53T 1,51T 1,36T 1,18T
Total Liabilities 681,09B 777,03B 865,32B 844,60B 785,55B
Shareholders' Equity 751,73B 757,19B 640,09B 510,17B 394,33B
Total Debt 229,10B 299,62B 340,06B 386,13B 355,26B
Cash & Equivalents 252,53B 340,93B 164,55B 294,58B 173,28B
Current Assets 679,44B 800,34B 726,36B 694,61B 580,07B
Current Liabilities 425,36B 431,70B 461,89B 376,25B 328,39B

Strategiescores

This stock passed the criteria for 5 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#322 of 1024
54
Custom Deep Value Investing (Seth Klarman)
#130 of 820
61
Custom Contrarian Investing (David Dreman)
#649 of 658
1
Value Defensive Investing (Benjamin Graham)
#359 of 708
28
Custom Balanced Risk
#112 of 148
39

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026
Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Contrarian Investing (David Dreman)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026
Ingestapt Balanced Risk
Mar 24, 2026